Cashing in with off-the-shelf CAR Ts

Nature Reviews Drug Discovery 17, 307 (2018). doi:10.1038/nrd.2018.69 Author: Asher Mullard Allogene Therapeutics is taking over rights to Pfizer's off-the-shelf chimeric antigen receptor (CAR) T cell pipeline, backed by US$300 million from one of the largest series A funding rounds in the history of biotech.Last year the FDA approved the first ever CAR Ts,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research